

CHM-8304

Assignment 1

Professor: Dr. Louis Barriault

Student Name(s):


Student Number(s):

Deadline: Electronic submission of the assignment to lbarriau@uottawa.ca (subject CHM-8304 assignment 1) by February 3, 2017 11:59 pm. After the deadline, there will be a penalty of 5 pts per day.


N.B. No more than 4 students per assignment. Please provide all the necessary reference (if needed)

1. By applying the principles of retrosynthetic analysis, show how each of the indicated target molecules could be prepared from the starting material given. No more than four or five separate transformations are necessary in any of the syntheses **(20 pts)**


1.1



1.2



1.3



2. Read the attached paper on the total synthesis of (+)-ryanodol by Reisman et al. Provide a valuable reaction mechanism for each steps displayed in Figure 2 and explain the diastereoselectivity when applicable **(80 pts)**

REPORTS

ORGANIC SYNTHESIS

A 15-step synthesis of (+)-ryanodol

Kangway V. Chuang,* Chen Xu,* Sarah E. Reisman†

(+)-Ryanodine and (+)-ryanodol are complex diterpenoids that modulate intracellular calcium-ion release at ryanodine receptors, ion channels critical for skeletal and cardiac muscle excitation-contraction coupling and synaptic transmission. Chemical derivatization of these diterpenoids has demonstrated that certain peripheral structural modifications can alter binding affinity and selectivity among ryanodine receptor isoforms. Here, we report a short chemical synthesis of (+)-ryanodol that proceeds in only 15 steps from the commercially available terpene (S)-pulegone. The efficiency of the synthesis derives from the use of a Pauson-Khand reaction to rapidly build the carbon framework and a SeO₂-mediated oxidation to install three oxygen atoms in a single step. This work highlights how strategic C–O bond constructions can streamline the synthesis of polyhydroxylated terpenes by minimizing protecting group and redox adjustments.

Terpenes are a large and structurally diverse family of natural products that range from simple hydrocarbons associated with flavors and fragrances, to complex, highly oxidized polycyclic molecules such as the antimalarial drug artemisinin, and the anticancer compounds ingenol and taxol (*1*). Although terpenes are isolated from natural sources, it can be challenging to translate their biological activity into a practical application (*2*). In some cases, the hurdle is low natural abundance; at other times, it is the difficulty encountered by chemists seeking to precisely edit a terpene's molecular structure to improve its drug-like properties or interrogate its role in modulating disease pathways. The development of concise chemical syntheses of terpenes can transform our ability to use these molecules and their synthetic derivatives as biological probes or as lead compounds for the development of new medicines (*3–5*). Furthermore, these scientific efforts often innovate chemical reactivity or synthetic design concepts (*6*).

The natural product ryanodine (**1**) (*7, 8*) and its hydrolysis product ryanodol (**2**) (*8, 9*) are among the most highly oxidized and synthetically challenging diterpenoids reported to date (Fig. 1A). Isolated from the tropical shrub *Ryania speciosa* Vahl in connection with its insecticidal properties (*7*), ryanodine is the namesake ligand of the ryanodine receptors (RyRs) (*10*), an important family of ion channels that regulate intracellular Ca²⁺ release and play a critical role in signal transduction (*11*). In mammalian cells, these receptors exist in multiple isoforms (RyR1, RyR2, and RyR3) that serve to mediate both movement and cognitive function. Mutations of RyRs are associated with genetic diseases such as malignant hyperthermia and central core disease (*12*), whereas altered ex-

pression of RyR2 and RyR3 has been associated with the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (*13*). Ryanodine binds with high affinity to the conducting state of RyRs, exerting concentration-dependent modulation of Ca²⁺ release: At nanomolar concentrations, ryanodine locks RyRs in an open, subconductance state, whereas at higher concentrations, ryanodine causes closure of the channels (*14*). The deacylated compound ryanodol binds with lower affinity than **1** to mammalian RyRs; however, it still induces a subconductance state and has been reported as a reversible probe of RyR-mediated Ca²⁺ release in cells (*15*).

Since the initial reports describing the isolation of ryanodine from *Ryania*, a number of congeners (known as ryanoids) that vary in oxidation pattern have been isolated (*16–20*). Whereas ryanodol—the compound obtained by hydrolysis of ryanodine—has not yet been isolated directly from a natural source, the closely related compound C3-*epi*-ryanodol (**4**) was isolated by González-Coloma from *Persea indica* (*18*). Indeed, owing to their structural similarities, C3-*epi*-ryanodol (**4**) was initially erroneously reported to be ryanodol (**2**); however, the structure of the Coloma-González isolate (*21*) was recently reassigned through the synthetic efforts of Inoue (see below) (*22*). These subtle differences in structure exert a pronounced effect on RyR binding: C3-*epi*-ryanodine (**5**), prepared from **4**, binds to RyRs with an affinity 1/100th that of **1** (*23*).

Given the biological importance of the RyRs, the ryanoids have been the focus of both total synthesis and derivatization efforts. In 1979, Deslongchamps and co-workers disclosed a total synthesis of (+)-**2**, which hinged on a key Diels-Alder cycloaddition and a series of elegantly designed intramolecular aldol reactions to assemble the tetracyclic ABCD framework (Fig. 1B) (*24–28*). In a classic example of relay synthesis, the degradation product (+)-anhydroryanodol (**3**) was converted to (+)-ryanodol (**2**) in a final two-step

sequence (*28*), providing the target molecule in 41 total steps (37 steps in its longest linear sequence). A more recent series of studies from Inoue and co-workers highlighted the utility of several radical-based C–O and C–C bond-forming reactions in a total synthesis that furnishes (±)-**2** (*29*) and (±)-**4** (*22*), each in 35 total steps. These studies allowed Inoue *et al.* to correctly reassign the structure of the natural product isolated from *P. indica* (*18*) as C3-*epi*-ryanodol (**4**). Inoue and co-workers subsequently reported that their synthesis could be rendered enantioselective through a catalytic asymmetric desymmetrization process and that an appropriately protected derivative of (+)-**2** could be elaborated to (+)-**1** in five synthetic steps (*30, 31*). In addition to these total syntheses, several medicinal chemistry studies have focused on the derivatization of ryanodine and ryanodol (*32–34*). Here, we disclose a direct and concise strategy to access the central ryanoid ring system, which has enabled the chemical synthesis of (+)-ryanodol (**2**) in only 15 steps from commercially available starting materials. These studies provide a synthetic platform from which it will be possible to prepare previously inaccessible ryanoid derivatives.

Perhaps the most substantial synthetic challenge embedded within the structure of **2** is the highly oxidized five-membered A-ring, which bears an all-carbon quaternary center and four additional stereogenic carbons bonded to oxygen (Fig. 1A). A concise synthesis of **2** requires a carefully choreographed introduction of these moieties to minimize redox, protecting group, and functional group transformations. Guided by the landmark studies of Deslongchamps and co-workers (*28*), we identified the C1–C15 bond of ryanodol (**2**) as the most simplifying and strategic initial retrosynthetic disconnection (Fig. 1B). This analysis revealed the tetracyclic lactone anhydroryanodol (**3**) as our initial synthetic target (Fig. 1C), with the isopropyl group introduced at a late stage through a transition metal-catalyzed cross-coupling reaction of enol triflate **6**; this approach would also allow for versatile incorporation of alternative carbon-based fragments to facilitate long-term goals of preparing ryanoid derivatives. We anticipated that the requisite A-ring oxidation pattern could be accessed via chemo- and stereoselective functionalization of cyclopentenone **7**, whereby the enone would provide a functional group handle to install the critical C3, C4, and C12 alcohols of **2**. We envisioned preparing cyclopentenone **7** by an intramolecular Pauson-Khand reaction (*35*), a transformation that would be facilitated by the conformational rigidity of bicyclic lactone **8**. Lactone **8** could arise through a series of transformations from (S)-pulegone, a commercially available terpene. By this analysis, the oxygen atoms at C6, C10, and C11 would be incorporated early in the synthesis, whereas the oxygen atoms at C3, C4, and C12 would be introduced at a late stage. With the implementation of appropriate protecting groups, we anticipated that this strategy would minimize synthetic manipulations ancillary to the direct construction of the natural product.

Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.

*These authors contributed equally to this work. †Corresponding author. Email: reisman@caltech.edu

We first investigated the stereoselective oxidation of (*S*)-pulegone (**10**) to install the C6 and C10 alcohols of the C-ring (Fig. 2), envisioning functionalization at both carbons via enolates accessed by γ - or α' -deprotonation of the ketone, respectively. Preliminary experiments confirmed that the C6-alcohol could be installed with 2.5:1 diastereomeric ratio (dr) through generation of the thermodynamic dienolate with potassium hexamethyldisilazide (KHMDs) followed by quenching with oxaziridine **11** (36). Noting that KHMDs did not appear to directly react with oxaziridine **11** at -78°C , we hypothesized that a one-step protocol involving excess KHMDs and **11** might simultaneously install both alcohols. Indeed, treatment of **10** with 2.5 equivalents (equiv.) of KHMDs at -78°C followed by dropwise addition of 2.4 equiv. of **11** provided α,α' -diol **12**, which could be isolated as a single diastereomer in 42% yield (120 mmol scale). Although the yield is modest, this single transformation converts a simple terpene to a valuable building block with the requisite ryanodol C-ring oxidation pattern. We improved the efficiency of this transformation to 50% yield by modification of the standard procedure on a smaller scale (10 mmol, see supplementary materials). However, given the operational simplicity of the former procedure on larger scales, this protocol was preferentially employed for increased material throughput.

Treatment of diol **12** with excess benzyl chloromethyl ether effected protection of both alcohols as benzyloxymethyl ethers to give **13**. At this stage, the D-ring was constructed by an efficient four-step sequence. First, addition of propynylmagnesium bromide to **13** at 0°C proceeded in 5:1 dr, providing the equatorially disposed alkyne in 81% isolated yield. Ozonolytic cleavage of the 1,1-disubstituted olefin proceeded in high yield to afford methyl ketone **14**. Although a *N,N'*-dicyclohexylcarbodiimide-mediated phosphonoacylation and intramolecular Horner-Wadsworth-Emmons lactone synthesis had proved moderately effective in model studies lacking C10 oxidation, the tertiary alkynol of **14** proved resistant to acylation under a number of conditions. Presumably, the increased steric encumbrance and inductively withdrawing C10-ether sharply decreases the nucleophilicity of the tertiary alkynol. Instead, ketone **14** was efficiently converted to α,β -unsaturated lactone **15** via 1,2-addition of ethoxyethynylmagnesium bromide followed by an Ag-catalyzed cyclization and elimination cascade (37).

With lactone **15** in hand, 1,4-addition of magnesium divinyl cuprate provided the corresponding enyne **16** as a single diastereomer in 84% yield, forging the critical all-carbon quaternary center at C5 while simultaneously setting the stage for a key Pauson-Khand cyclization. A number of Pauson-Khand procedures were screened for their ability to deliver **17** in both high yield and diastereoselectivity (Table 1). Although standard conditions (38, 39) using stoichiometric amounts of $\text{Co}_2(\text{CO})_8$ produced the desired product, separation of diastereomeric enone **17'** proved challenging and indicated that a more selective protocol was necessary. Monometallic




Fig. 1. Ryanodine and selected ryanoids. (A) Chemical structures of (+)-ryanodine (**1**), (+)-ryanodol (**2**), (+)-anhydroryanodol (**3**), 3-epi-ryanodol (**4**), and 3-epi-ryanodine (**5**). (B) Carbon numbering and ring system letter assignment. (C) Retrosynthetic analysis of anhydroryanodol.




Table 1. Evaluation of Pauson-Khand reaction conditions.

Entry	Conditions*	dr [†]	Yield (%) [‡]
1	$\text{Co}_2(\text{CO})_8$ (1.2 equiv.), THF, 12 hours; then DMSO, 65°C	2.2:1	46
2	$\text{Co}_2(\text{CO})_8$ (1.2 equiv.), CH_2Cl_2 , 9 hours; then NMO, 23°C	4.5:1	78
3	$\text{Mo}(\text{CO})_6$ (1.2 equiv.), DMSO, PhMe, 110°C	—	Trace
4	$\text{Mo}(\text{CO})_3(\text{DMF})_3$ (1.1 equiv.), CH_2Cl_2 , 23°C	>20:1	67
5	$[\text{RhCl}(\text{CO})_2]_2$ (1 mol %), CO (1 atm), <i>m</i> -xylene, 110°C	>20:1	85

*Reactions conducted on 0.2 mmol scale. THF, tetrahydrofuran; DMSO, dimethylsulfoxide; NMO, *N*-methylmorpholine *N*-oxide; DMF, *N,N*-dimethylformamide. [†]Determined by ^1H -NMR spectroscopy. [‡]Isolated yield after purification by silica gel chromatography.




Fig. 2. Complete synthetic sequence for the chemical synthesis of (+)-anhydroryanodol and (+)-ryanodol. Reagents and conditions as follows: 1. potassium hexamethyldisilazide (2.5 equiv.), THF, -78°C ; then **11** (2.4 equiv.), 42 to 50% yield. 2. Benzyl chloromethyl ether (5.0 equiv.), *i*Pr₂NEt (8.0 equiv.), ^{*n*}Bu₄Ni (2.0 equiv.), CH₂Cl₂, 50°C , 65% yield. 3. Propynylmagnesium bromide, THF, 0°C , 81% yield, 5:1 dr. 4. O₃/O₂, CH₂Cl₂/MeOH (4:1), -78°C ; then PPh₃, 91% yield. 5. Ethoxyethynylmagnesium bromide (5.0 equiv.), THF, 0°C , 75% yield. 6. AgOTf (2 mol %), PhMe, 0°C , 90% yield. 7. CuI (3.0 equiv.), vinylmagnesium

bromide (6.0 equiv.), THF, -78°C to -30°C , 84% yield. 8. [RhCl(CO)₂]₂ (1 mol %), CO (1 atm), *m*-xylene, 110°C , 85% yield. 9. SeO₂ (10 equiv.), 4 Å MS, 1,4-dioxane, 110°C . 10. Comins' reagent, *i*Pr₂NEt, CH₂Cl₂, -78° to 0°C , 28% yield, two steps. 11. PdCl₂(PPh₃)₂, tributyl(prop-1-en-2-yl)stannane, LiCl, 2-MeTHF, 85°C , 64% yield. 12. LiBH₄, THF, -15° to -10°C ; then KHF₂/MeOH. 13. H₂, Pd(OH)₂/C, EtOH, 22°C (61% yield, two steps). 14. Trifluoroacetic anhydride, urea hydrogen peroxide, Na₂HPO₄, 86% yield. 15. Li⁰ wire, NH₃/THF, -78°C , 38% yield.

mediators were found to improve the dr, with Mo(CO)₃(DMF)₃ (**40**) providing **17** as a single diastereomer in 67% yield. Despite the serviceable yield and scalability of this transformation, we sought a more efficient protocol that could obviate the need for stoichiometric metals and their attendant by-products. Treatment of **16** with 1 mol % [RhCl(CO)₂]₂ (**41**) under an atmosphere of carbon monoxide provided the desired product in 85% yield, again as a single diastereomer. This reaction has been conducted on a multigram scale, providing 5.7 g of enone **17** in a single pass. Single-crystal x-ray diffraction analysis of **17** confirmed both the absolute configuration and structural assignment of this key tetracyclic intermediate.

The successful realization of the Pauson-Khand cyclization led us to the next phase of our synthetic studies: chemo- and stereoselective functionalization of the A-ring through the introduction of the C3, C4, and C12-alcohols, as well as the C2-isopropyl unit. To this end, initial investigations were aimed at oxidation of the C4 allylic methine of **17**, but efforts in this vein were thwarted by undesired reactivity. For example, established methods for allylic oxidation via reactive radical species

[e.g., Pd(OH)₂/C/*t*-BuOOH (**42**) or Rh₂(cap)₄/*t*-BuOOH (**43**)] were unfruitful owing to competitive functionalization of the C1–C12 olefin (i.e., epoxidation, 1,2-difunctionalization). Although we considered the possibility of advancing these unanticipated products further in the synthesis, it was unclear how to achieve efficient transposition to the requisite oxidation pattern.

Instead, we turned to C3-functionalization of **17** using SeO₂ (**44**), anticipating that the enone might be readily oxidized to the corresponding α -diketone (Fig. 3). We found that treatment of **17** with excess SeO₂ in wet 1,4-dioxane at 110°C not only effected C3-oxidation, but also the formal hydration of the enone, thereby installing the necessary C12-alcohol and providing diosphenol **21**. Hypothesizing that rigorous exclusion of water might promote C4-allylic hydroxylation before diketone formation, we subjected enone **17** to SeO₂ under anhydrous conditions in the presence of 4 Å molecular sieves (4 Å MS). Prolonged heating at 110°C in 1,4-dioxane provided a distinct product, which had incorporated an additional oxygen as determined by mass spectrometry analysis. Rigorous structural assignment of this compound revealed it to be the

fully oxidized diosphenol **18**, a compound with the C4, C12 *syn*-vicinal diol of **2**. This single-step transformation installs the necessary oxygen atoms at C3, C4, and C12 while simultaneously providing a functional group handle for incorporation of the C2-isopropyl group.

Because C4-deoxy analog of ryanodine is itself a natural product, deoxyspiganthine (**20**), and could be of interest for future biological studies, we optimized procedures to prepare both **18** and **21** (Fig. 3). Given concerns that contamination by ¹H-nuclear magnetic resonance (¹H-NMR) silent, red selenium by-products resulted in artificially inflated isolated yields, our optimization efforts were guided by ¹H-NMR yields determined by integration versus an added standard. Isolated yields were determined after conversion to corresponding enol triflates **19** and **22**, which could be obtained as analytically pure compounds. Thus, subsection of tetracycle **17** to 10 equiv. of SeO₂ in wet 1,4-dioxane at 110°C for 1 hour provided **21** in 67 to 69% ¹H-NMR yield, and the corresponding vinyl triflate **22** in 56% isolated yield over two steps. Alternatively, treatment of **17** with 10 equiv. of SeO₂ in anhydrous 1,4-dioxane in the presence of freshly




Fig. 3. Selenium dioxide-mediated A-ring oxidation. In the presence of water, SeO_2 -mediated oxidation of enone **17** provides **21**. In the absence of water, further oxidation occurs to deliver **18**.

activated 4 Å MS at 110°C for 9 hours provided **18** in 33 to 35% ^1H -NMR yield, and vinyl triflate **19** in 28% isolated yield over two steps. Despite the modest yield, this sequence accomplishes the stereospecific incorporation of three oxygen atoms, proceeds with an average efficiency of ~70% yield per transformation, and fares well in comparison to conceivable multiple step protocols to achieve the same reactivity. Although the precise mechanism of the SeO_2 -mediated oxidation remains unclear at this time, investigations are ongoing and should aid the development of a more efficient protocol.

In the final stages of the synthesis, advancement of **19** to (+)-anhydroryanodol was achieved by a three-step sequence. Palladium-catalyzed cross-coupling between **19** and tributyl(2-propenyl)stannane installed the final three carbons, delivering **20** in 64% yield. LiBH_4 -mediated 1,2-reduction stereoselectively furnished the C3 alcohol, which was subjected to H_2 and $\text{Pd}(\text{OH})_2/\text{C}$ to simultaneously reduce the disubstituted olefin and remove the benzyloxymethyl groups, providing (+)-**3** in 61% yield over two steps. Using this route, we have prepared >400 mg of (+)-anhydroryanodol to date. Conversion of this material to (+)-ryanodol was achieved via a slight modification of Deslongchamps's two-step protocol (28). Treatment of **3** with trifluoroacetic acid, freshly prepared from trifluoroacetic anhydride and urea hydrogen peroxide (in place of the originally reported concentrated hydrogen peroxide), cleanly afforded epianhydroryanodol epoxide in 86% yield. Subjection of this material to Li^0 in NH_3 (distilled from Na^0) at -78°C resulted in reductive cyclization to produce (+)-**2** in 38% yield (lit. 60% yield). In our hands, the reaction profile was highly dependent on the purity of the ammonia. Specifically, independent control reactions conducted with ammonia condensed directly from the gas cylinder, or using redistilled ammonia with either added H_2O (10 equiv.), or exogenous Fe-salts (45), revealed that these parameters all substantially affect the ratio of **2** to carbonyl-reduction products, as well as the formation of minor unidentified degradation products.

The concise synthesis of (+)-ryanodol described here proceeds in only 15 synthetic steps (0.42% overall yield) from (*S*)-pulegone (**10**), fewer than half the steps of the previously disclosed syntheses by Deslongchamps *et al.* (37 linear steps, 0.23% yield) and Inoue *et al.* (35 linear steps, 0.008% yield). The efficiency of our approach derives from the development of a direct and scalable route to key cyclopentenone **17**, which can be prepared on a multigram scale in only eight steps and rapidly elaborated to (+)-anhydroryanodol. The strategic use of C–O bond-forming reactions minimizes redox adjustments and the use of protecting groups. Indeed, the five alcohols found in (+)-**3** are incorporated with just two transformations: the dihydroxylation of **10** and the SeO_2 -mediated oxidation of enone **17**. Moreover, all but the C3-alcohol are introduced with the correct carbon oxidation level. We anticipate that the brevity of the synthesis will render feasible the design and preparation of ryanoid derivatives for studying RyR function.

REFERENCES AND NOTES

- E. Breitmaier, *Terpenes: Flavors, Fragrances, Pharmacology, Pheromones* (Wiley, Weinheim, Germany, 2006).
- F. E. Koehn, G. T. Carter, *Nat. Rev. Drug Discov.* **4**, 206–220 (2005).
- L. Jørgensen *et al.*, *Science* **341**, 878–882 (2013).
- S. Kawamura, H. Chu, J. Felding, P. S. Baran, *Nature* **532**, 90–93 (2016).
- H.-H. Lu, M. D. Martinez, R. A. Shenvi, *Nat. Chem.* **7**, 604–607 (2015).
- T. J. Maimone, P. S. Baran, *Nat. Chem. Biol.* **3**, 396–407 (2007).
- E. F. Rogers, F. R. Koniuszy, J. Shavel Jr., K. Folkers, *J. Am. Chem. Soc.* **70**, 3086–3088 (1948).
- K. Wiesner, Z. Valenta, J. A. Findlay, *Tetrahedron Lett.* **8**, 221–223 (1967).
- S. N. Srivastava, M. Przybylska, *Can. J. Chem.* **46**, 795–797 (1968).
- I. N. Pessah, A. L. Waterhouse, J. E. Casida, *Biochem. Biophys. Res. Commun.* **128**, 449–456 (1985).
- J. T. Lanner, D. K. Georgiou, A. D. Joshi, S. L. Hamilton, *Cold Spring Harb. Perspect. Biol.* **2**, a003996 (2010).
- T. V. McCarthy, K. A. Quane, P. J. Lynch, *Hum. Mutat.* **15**, 410–417 (2000).
- M. Kellier *et al.*, *Neuroscience* **92**, 499–513 (1999).
- G. Meissner, *J. Biol. Chem.* **261**, 6300–6306 (1986).
- J. Ramos-Franco *et al.*, *Pflügers Arch.* **460**, 767–776 (2010).

- A. Isogai, S. Murakoshi, A. Suzuki, S. Tamura, *Agric. Biol. Chem.* **41**, 1779–1784 (1977).
- T. Nohara, N. Tokubuchi, M. Kuroiwa, I. Nishioka, *Chem. Pharm. Bull. (Tokyo)* **28**, 2682–2686 (1980).
- A. González-Coloma, M. G. Hernandez, A. Perales, B. M. Fraga, *J. Chem. Ecol.* **16**, 2723–2733 (1990).
- A. González-Coloma, D. Terrero, A. Perales, P. Escoubas, B. M. Fraga, *J. Agric. Food Chem.* **44**, 296–300 (1996).
- H. Achenbach, H. Hübner, W. Vierling, W. Brandt, M. Reiter, *J. Nat. Prod.* **58**, 1092–1096 (1995).
- This compound has been referred to by Inoue *et al.* as “natural ryanodol.” See (22).
- M. Koshimizu, M. Nagatomo, M. Inoue, *Angew. Chem. Int. Ed. Engl.* **55**, 2493–2497 (2016).
- W. Welch *et al.*, *Biochemistry* **36**, 2939–2950 (1997).
- A. Bélanger *et al.*, *Can. J. Chem.* **57**, 3348–3354 (1979).
- P. Deslongchamps *et al.*, *Can. J. Chem.* **68**, 115–126 (1990).
- P. Deslongchamps *et al.*, *Can. J. Chem.* **68**, 127–152 (1990).
- P. Deslongchamps *et al.*, *Can. J. Chem.* **68**, 153–185 (1990).
- P. Deslongchamps *et al.*, *Can. J. Chem.* **68**, 186–192 (1990).
- M. Nagatomo *et al.*, *J. Am. Chem. Soc.* **136**, 5916–5919 (2014).
- M. Nagatomo *et al.*, *Chemistry* **22**, 222–229 (2016).
- K. Masuda, M. Koshimizu, M. Nagatomo, M. Inoue, *Chemistry* **22**, 230–236 (2016).
- A. L. Waterhouse, I. N. Pessah, A. O. Francini, J. E. Casida, *J. Med. Chem.* **30**, 710–716 (1987).
- W. Welch *et al.*, *Biochemistry* **33**, 6074–6085 (1994).
- J. L. Sutko, J. A. Airey, W. Welch, L. Ruest, *Pharmacol. Rev.* **49**, 53–98 (1997).
- I. U. Khand, G. R. Knox, P. L. Pauson, W. E. Watts, M. I. Foreman, *J. Chem. Soc. Perkin Trans. I* **1973**, 977–981 (1973).
- L. C. Vishwakarma, O. D. Stringer, F. A. Davis, *Org. Synth.* **66**, 203–207 (1988).
- M. Egi *et al.*, *Org. Lett.* **15**, 4150–4153 (2013).
- Y. K. Chung, B. Y. Lee, N. Jeong, M. Hudecek, P. L. Pauson, *Organometallics* **12**, 220–223 (1993).
- S. Shambayani, W. E. Crowe, S. L. Schreiber, *Tetrahedron Lett.* **31**, 5289–5292 (1990).
- M. R. Adrio, *Org. Lett.* **7**, 431–434 (2005).
- Y. Koga, T. Kobayashi, K. Narasaka, *Chem. Lett.* **27**, 249–250 (1998).
- J.-Q. Yu, E. J. Corey, *Org. Lett.* **4**, 2727–2730 (2002).
- A. J. Catino, R. E. Forslund, M. P. Doyle, *J. Am. Chem. Soc.* **126**, 13622–13623 (2004).
- R. Riley, J. F. Morley, N. A. C. Friend, *J. Chem. Soc.* **1932**, 1875–1883 (1932).
- R. G. Harvey, K. Urberg, *J. Org. Chem.* **33**, 2570–2571 (1968).

ACKNOWLEDGMENTS

The California Institute of Technology Center for Catalysis and Chemical Synthesis is gratefully acknowledged for access to analytical equipment. We thank S. Virgil and J. Hofstra for assistance in obtaining x-ray-quality crystals and solving the structure of **15**, respectively. M. Takase and L. Henling are acknowledged for acquiring the x-ray diffraction data for **15** (CCDC deposition no. 1478621; the data are available free of charge from The Cambridge Crystallographic Data Centre). M. Kieffer is gratefully acknowledged for critical feedback and helpful suggestions. Fellowship support was provided by the National Science Foundation (graduate research fellowship to K.V.C., grant DGE-1144469) and the Shenzhen UV-ChemTech Inc. (postdoctoral fellowship to C.X.). S.E.R. is an American Cancer Society Research Scholar and Heritage Medical Research Institute investigator. Financial support from the NIH (National Institute of General Medical Sciences grant RGM097582-01), Eli Lilly, and Novartis is gratefully acknowledged. The California Institute of Technology has filed a provisional patent on this work (application no. 62/269,760).

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/353/6302/912/suppl/DC1
Materials and Methods
Schemes S1 and S2
Tables S1 to S9
References (46–53)
NMR Spectra

9 May 2016; accepted 25 July 2016
10.1126/science.aag1028



A 15-step synthesis of (+)-ryanodol

Kangway V. Chuang, Chen Xu and Sarah E. Reisman (August 25, 2016)

Science **353** (6302), 912-915. [doi: 10.1126/science.aag1028]

EXTENDED PDF FORMAT
SPONSORED BY



Editor's Summary

Rapid ryanodol route

The plant-derived compound ryanodine and its hydrolyzed cousin ryanodol are biochemically interesting for their calcium-regulating capacity and chemically interesting for their dense tangle of carbon rings brimming with oxygen appendages. Chuang *et al.* report an efficient 15-step asymmetric synthesis of ryanodol from the structurally much simpler terpene pulegone (see the Perspective by Verdaguer). Key steps include a Pauson-Khand cyclization of a tethered alkene and alkyne with carbon monoxide to set the ring motifs, followed by an oxidation using selenium dioxide that delivers three different oxygen substituents in tandem.

Science, this issue p. 912; see also p. 866

This copy is for your personal, non-commercial use only.

Article Tools

Visit the online version of this article to access the personalization and article tools:

<http://science.sciencemag.org/content/353/6302/912>

Permissions

Obtain information about reproducing this article:

<http://www.sciencemag.org/about/permissions.dtl>

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.